ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / SNWV / insiders
SRTS (41) DAVI (47) MDAI (16) XTNT (65) ⌘ Pro Terminal β†’

SANUWAVE Health Inc. (SNWV) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$5.85 +13.59% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.98

SANUWAVE Health Inc. (SNWV) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $44.3M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SNWV Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is SNWV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, SANUWAVE Health Inc. (NASDAQ: SNWV) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $5.85 (+13.59% 1D, market cap $44.3M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 18/20. Across 1015 tracked Health Care issuers, SNWV ranks #255 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does SNWV compare to SRTS and DAVI in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), SNWV carries a Roarable D (51/100 RQD), trailing P/E of 3.8x, gross margin of 77.1%, and ROIC of 67.3%. By comparison, SRTS (Sensus Healthcare Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -31.3%, cap $45.4M) and DAVI (Davion Healthcare Plc) posts a D grade (47/100 RQD, P/E N/A, ROIC β€”, cap $42.0M). Among the 5-stock peer group, SNWV leads on earnings multiple (3.8x) while SNWV leads on capital efficiency (67.3% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SNWV?
β–Ό

Per SNWV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001417663), SANUWAVE Health Inc. generated $44.1M in revenue (+36.3% YoY), $11.8M in net income, and $1.9M in free cash flow against $37.3M in total assets and $16.1M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.98 (+2.26%)🧬 Cannibal Buyback (-2.92% YoY Shares)βš™οΈ Cash Engine: 11/20 (D+) β€’ 4.4% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY β€’ 49.7% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510051
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C- Β· Rk D-
Cash (11)Whales (7)SEC (10)Macro (5)CEO (18)
Each axis scored 0–20
12M PRICE TARGET CONE-3.1% Base Target
$38 Bull$6 Base$4 Bear
πŸ“¬ FREE SNWV RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for SNWV)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (51/100 Composite)
πŸ” WHY SNWV SCORES 51/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (35% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy β€’ Cannibal Buyback (-2.92% YoY Shares)

β–² #2 Bullish Driver: Cash Engine Quality+11/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 4.4% FCF Margin ($1.9M FCF) & 77.1% Gross Margin

β–Ό #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)

Macro rate sensitivity & RSI-14 (50.1) create a -15 pt regime headwind

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
43
Grade D$5.61-6.1% Next Q
Q2 (-2Q)
46
Grade D$5.27-2.7% Next Q
Q3 (-1Q)
48
Grade D$5.13+14% Next Q
Current
51
Grade D$5.85-1.3% Hist 90D Ξ±
Trajectory: D (43) β†’ D (51)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a SNWV Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While SNWV currently carries a cautious 51/100 (D) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Company leadership has skin in the game with net positive insider conviction.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.84) and Max Pain ($6.14) forces dealer call-delta covering toward $38.01.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-2.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SNWVβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œSNWV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

SNWV Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SNWV)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SNWV. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SNWV)

  • βœ“Walkthrough of SNWV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
SNWV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -62.60%β–² RESISTANCE BREAKOUT
2026-11-03O $5.27H $5.85L $5.15C $5.85VOL 11.9K
RES: $4.20SUP: $1.91SMA50: $4.84SMA200: $13.27
$31.43$23.97$16.52$9.06$1.61RES $4.20SUP $1.91$5.852026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SNWV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ SNWV Butterfly Map β†’ + Track SNWV β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-15.0%/yr Implied 5Y Growth

vs. +36.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SNWV today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for SNWV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SNWV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SNWV)

Health Care Rank #255 of 1015 βš”οΈ SRTS vs SNWV Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (SNWV vs. SRTS, DAVI, MDAI, XTNT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, SANUWAVE Health Inc. (SNWV) ranks #255 by composite RQD confidence (51/100, grade D) and #763 by equity capitalization ($44.3M). Within this direct 5-issuer industry benchmark cohort, SNWV leads on earnings valuation at 3.8x trailing P/E, while SNWV leads on capital efficiency and profitability with 67.3% ROIC and 77.1% gross margin. XTNT currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with SNWV at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SNWV ACTIVE
SANUWAVE Health Inc.
D 51/100 3.8x 77.1% 67.3% +13.59% $44.3M Benchmark Subject
SRTS
Sensus Healthcare Inc.
D- 41/100 β€” 43.2% -31.3% -0.36% $45.4M /srts-vs-snwv β†’
DAVI
Davion Healthcare Plc
D 47/100 β€” β€” β€” -11.31% $42.0M /davi-vs-snwv β†’
MDAI
Spectral AI Inc. (Class A)
E 16/100 β€” 45.4% -35.0% -0.65% $49.2M /mdai-vs-snwv β†’
XTNT
Xtant Medical Holdings Inc.
C 65/100 β€” 62.9% 12.8% -0.64% $39.3M /xtnt-vs-snwv β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001417663 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SANUWAVE Health Inc. (SNWV) reported GAAP revenue of $44.1M (+36.3% vs. FY2024 revenue of $32.3M , and +128.8% cumulative change since FY2023) , GAAP net income of $11.8M, operating cash flow of $3.9M, and free cash flow of $1.9M (-1.6% YoY). On the balance sheet, SNWV closed FY2025 with $37.3M in total assets against $16.1M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $44.1M $11.8M $3.9M $1.9M $37.3M $16.1M
FY2024 (FY) 2024-12-31 $32.3M -$33.1M $2.5M $2.0M $30.1M β€”
FY2023 (FY) 2023-12-31 $19.3M -$25.8M -$4.5M -$4.5M β€” β€”

3. SNWV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SNWV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, SANUWAVE Health Inc. (NASDAQ: SNWV) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $5.85 (+13.59% 1D, market cap $44.3M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 18/20. Across 1015 tracked Health Care issuers, SNWV ranks #255 in composite RQD confidence.

How does SNWV compare to SRTS and DAVI in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), SNWV carries a Roarable D (51/100 RQD), trailing P/E of 3.8x, gross margin of 77.1%, and ROIC of 67.3%. By comparison, SRTS (Sensus Healthcare Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -31.3%, cap $45.4M) and DAVI (Davion Healthcare Plc) posts a D grade (47/100 RQD, P/E N/A, ROIC β€”, cap $42.0M). Among the 5-stock peer group, SNWV leads on earnings multiple (3.8x) while SNWV leads on capital efficiency (67.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SNWV?

Per SNWV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001417663), SANUWAVE Health Inc. generated $44.1M in revenue (+36.3% YoY), $11.8M in net income, and $1.9M in free cash flow against $37.3M in total assets and $16.1M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SNWV trading relative to its 50-day, 200-day, and 52-week technical levels?

SNWV last traded at $5.85 (+13.59% on volume of 43,152 shares), positioning the stock +20.87% above its 50-day simple moving average ($4.84) and -55.92% below its 200-day simple moving average ($13.27). Across its 52-week range of $3.92 to $36.20, SNWV sits at the 6.0% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($5.12 to $6.58).

Direct Sub-Reports: SNWV RQD Cockpit SNWV 12M Forecast SNWV Earnings & Move SNWV Dividends & DRIP SNWV Insiders & 13F SNWV Whale Options SNWV Profit Sankey SNWV News & Why
ROARABLE RATING BRIEF β€’ RQD 51/100 (D) βœ“ SEC XBRL & RQD VERIFIED

SNWV β€” SANUWAVE Health Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

SANUWAVE Health Inc. (SNWV) earns a live Roarable RQD composite score of 51/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $5.85 (+13.59% 1D, market capitalization $44.3M).

  • Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of 67.3%, gross margin of 77.1%, operating margin of 11.2%, and free cash flow yield of 4.27%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (18/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 7/9, and Debt/Equity of 8.50x.

2. Business Model, Unit Margins & SEC Financial Trajectory

SANUWAVE Health Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry..0B in the profile field and $45.3M in market data. β€”: a detailed description of specific products, customers, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), SANUWAVE Health Inc. (SNWV) reported $44.1M in annual revenue (up from $32.3M in FY2024, +36.3% YoY) and $11.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($19.3M revenue, -$25.8M net income) through FY2025, SNWV scaled operating cash flow to $3.9M and free cash flow to $1.9M, backed by $37.3M in total assets against $16.1M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D β€’ RQD 51/100): Company leadership has skin in the game with net positive insider conviction. Free cash flow yield of 4.27% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $3.92 – $36.20 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 3.8x trailing P/E and 7.5x EV/EBITDA against 11.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Investors should therefore not infer upstream or downstream dependencies from the source data. The covenant waiver noted in the news wire suggests that lender terms are a 2nd-order sensitivity: if coverage ratios tighten again, the company may need further waivers, which would affect financing flexibility.

  • Key Question #1: Can SNWV sustain or expand its 11.2% operating margin and 67.3% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $44.1M and free cash flow of $1.9M, how will capital allocation balance growth reinvestment against $16.1M in total debt?
  • Key Question #3: How sensitive is SNWV's 3.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SNWV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SANUWAVE Health Inc. (SNWV) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to SNWV Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SNWV Bull vs. Bear Conversation Board β€” What's Your Call at $5.85?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SNWV 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SNWV:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER β€’ Growth & Tech Investor πŸ‚ BULLISH 🎯 Target: $6.03 (+17.1%)
πŸ“Œ Pinned Debate

Reported FY 2025 net income of $11.8M and a 3.8 TTM P/E suggest the market may be pricing in very little of the recent earnings turnaro

The street is overcomplicating SANUWAVE Health Inc. (SNWV). Reported FY 2025 net income of $11.8M and a 3.8 TTM P/E suggest the market may be pricing in very little of the recent earnings turnaround.. With an RQD score of 51/100 (D) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $5.56.

VolSurface_Trader πŸ‚ BULL

Both sides have a point here β€” SNWV's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER β€’ Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $4.22 (-18.1%)
Spot @ $5.15

A lender coverage-ratio waiver, a 52-week range of $3.92 to $36.2, and a D+ RQD grade point to fragile balance-sheet support.

A lender coverage-ratio waiver, a 52-week range of $3.92 to $36.2, and a D+ RQD grade point to fragile balance-sheet support.. Look at the math on SNWV: paying 3.8x trailing P/E for 67.3% ROIC and 11.2% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $4.53 before getting long.

LIVE TAPE